Regorafenib receives Priority Review for colorectal cancer

FDA accepted and granted Priority Review to an NDA from Bayer AG (Xetra:BAYN) for regorafenib to treat metastatic colorectal cancer. The company submitted the application at the end of April; a six-mo...